About ZYTIGA

ZYTIGA is a prescription medication containing the active ingredient Abiraterone Acetate. It is used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with prednisone. Abiraterone Acetate works by inhibiting the production of androgens, which are male hormones that can promote the growth of prostate cancer cells.

Key Benefits & Uses

Treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with prednisone.
Reduces the risk of death by 29% compared to prednisone alone in patients with mCRPC.
May be used in patients who have received prior chemotherapy.

Active Ingredient & Action

Abiraterone Acetate is a CYP17 inhibitor, which means it blocks the production of androgens, including testosterone, in the adrenal glands and testes. By reducing androgen levels, Abiraterone Acetate can slow the growth and spread of prostate cancer cells.

Important Notes

ZYTIGA should only be used under the guidance of a healthcare professional. Common side effects include hypertension, hypokalemia, and liver function abnormalities. Patients with severe liver impairment should not take ZYTIGA. It is essential to follow the recommended dosage and schedule to minimize the risk of adverse effects.